151 related articles for article (PubMed ID: 8352564)
1. Inhibition of DNA repair in cells treated with a combination of alkylating agents.
Frankfurt OS; Seckinger D; Sugarbaker EV
Anticancer Res; 1993; 13(4):947-52. PubMed ID: 8352564
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of DNA repair and the enhancement of cytotoxicity of alkylating agents.
Frankfurt OS
Int J Cancer; 1991 Jul; 48(6):916-23. PubMed ID: 1907257
[TBL] [Abstract][Full Text] [Related]
3. Flow cytometric analysis of DNA damage and repair in the cells resistant to alkylating agents.
Frankfurt OS; Seckinger D; Sugarbaker EV
Cancer Res; 1990 Aug; 50(15):4453-7. PubMed ID: 2369722
[TBL] [Abstract][Full Text] [Related]
4. Intercellular transfer of drug resistance.
Frankfurt OS; Seckinger D; Sugarbaker EV
Cancer Res; 1991 Feb; 51(4):1190-5. PubMed ID: 1997161
[TBL] [Abstract][Full Text] [Related]
5. Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells.
Han I; Ling YH; al-Baker S; Khokhar AR; Perez-Soler R
Cancer Res; 1993 Oct; 53(20):4913-9. PubMed ID: 8402681
[TBL] [Abstract][Full Text] [Related]
6. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
7. DNA repair mechanisms are involved in the hypoxia-dependent toxicity of NLCQ-1 (NSC 709257) and its synergistic interaction with alkylating agents.
Papadopoulou MV; Bloomer WD
In Vivo; 2007; 21(2):175-80. PubMed ID: 17436565
[TBL] [Abstract][Full Text] [Related]
8. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
9. Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression.
Li QQ; Yunmbam MK; Zhong X; Yu JJ; Mimnaugh EG; Neckers L; Reed E
Cell Mol Biol (Noisy-le-grand); 2001; 47 Online Pub():OL61-72. PubMed ID: 11936875
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents.
Hawkins DS; Demers GW; Galloway DA
Cancer Res; 1996 Feb; 56(4):892-8. PubMed ID: 8631030
[TBL] [Abstract][Full Text] [Related]
11. 1-beta-D-arabinofuranosylcytosine and hydroxyurea production of cytotoxic synergy with cis-diamminedichloroplatinum(II) and modification of platinum-induced DNA interstrand cross-linking.
Swinnen LJ; Barnes DM; Fisher SG; Albain KS; Fisher RI; Erickson LC
Cancer Res; 1989 Mar; 49(6):1383-9. PubMed ID: 2924295
[TBL] [Abstract][Full Text] [Related]
12. Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens.
Cheng MF; Chatterjee S; Berger NA
Oncol Res; 1994; 6(6):269-79. PubMed ID: 7865902
[TBL] [Abstract][Full Text] [Related]
13. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo.
Teicher BA; Holden SA; Eder JP; Brann TW; Jones SM; Frei E
Cancer Res; 1989 Nov; 49(21):5994-8. PubMed ID: 2790813
[TBL] [Abstract][Full Text] [Related]
14. Establishment of an in vitro model for cisplatin resistance in human neuroblastoma cell lines.
Ireland CM; Pittman SM; Jones SL; Harnett PR
Anticancer Res; 1994; 14(6B):2397-403. PubMed ID: 7872659
[TBL] [Abstract][Full Text] [Related]
15. Cell death and DNA fragmentation induced by liposomal platinum(II) complex, L-NDDP in A2780 and A2780/PDD cells.
Han I; Ling YH; Khokhar AR; Perez-Soler R
Anticancer Res; 1994; 14(2A):421-6. PubMed ID: 8017841
[TBL] [Abstract][Full Text] [Related]
16. Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair.
Yang LY; Li L; Keating MJ; Plunkett W
Mol Pharmacol; 1995 May; 47(5):1072-9. PubMed ID: 7746274
[TBL] [Abstract][Full Text] [Related]
17. Effect of DNA-repair-enzyme modulators on cytotoxicity of L-phenylalanine mustard and cis-diamminedichloroplatinum (II) in mammary carcinoma cells resistant to alkylating drugs.
Alaoui-Jamali M; Loubaba BB; Robyn S; Tapiero H; Batist G
Cancer Chemother Pharmacol; 1994; 34(2):153-8. PubMed ID: 8194166
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of pentoxifylline as a modulator of alkylating agent activity in vitro and in vivo.
Teicher BA; Holden SA; Herman TS; Epelbaum R; Pardee AB; Dezube B
Anticancer Res; 1991; 11(4):1555-60. PubMed ID: 1746913
[TBL] [Abstract][Full Text] [Related]
19. Nucleotide excision repair in the human ovarian carcinoma cell line (2008) and its cisplatin-resistant variant (C13*).
Moorehead RA; Armstrong SG; Rainbow AJ; Singh G
Cancer Chemother Pharmacol; 1996; 38(3):245-53. PubMed ID: 8646799
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms involved in the potentiation of melphalan by the bioreductive compound THNLA-1 in vitro.
Papadopoulou MV; Ji M; Khan SH; Bloomer WD
Oncol Res; 1999; 11(8):345-57. PubMed ID: 10803738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
